Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Mitogen-activated protein kinase 14 | ||
| Ligand | BDBM50175759 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_328207 (CHEMBL863946) | ||
| IC50 | 6.8±n/a nM | ||
| Citation |  Bao, J; Hunt, JA; Miao, S; Rupprecht, KM; Stelmach, JE; Liu, L; Ruzek, RD; Sinclair, PJ; Pivnichny, JV; Hop, CE; Kumar, S; Zaller, DM; Shoop, WL; O'neill, EA; O'keefe, SJ; Thompson, CM; Cubbon, RM; Wang, R; Zhang, WX; Thompson, JE; Doherty, JB p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett16:64-8 (2005) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Mitogen-activated protein kinase 14 | |||
| Name: | Mitogen-activated protein kinase 14 | ||
| Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 41286.76 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Q16539 | ||
| Residue: | 360 | ||
| Sequence: |
| ||
| BDBM50175759 | |||
| n/a | |||
| Name | BDBM50175759 | ||
| Synonyms: | 7-(1-tert-butylpiperidin-4-yl)-5-(2-chlorophenyl)-1-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-one | CHEMBL424666 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C29H28Cl3N3O | ||
| Mol. Mass. | 540.911 | ||
| SMILES | CC(C)(C)N1CCC(CC1)c1cc2n(-c3c(Cl)cccc3Cl)c(=O)ccc2c(n1)-c1ccccc1Cl |(34.74,5.09,;33.42,4.32,;34.19,2.98,;32.64,5.65,;32.08,3.55,;32.08,2.01,;30.75,1.24,;29.41,2,;29.41,3.54,;30.75,4.31,;28.08,1.23,;26.74,1.99,;25.41,1.22,;24.08,1.99,;24.08,3.52,;22.75,4.29,;21.42,3.52,;22.75,5.82,;24.09,6.6,;25.42,5.83,;25.42,4.29,;26.75,3.52,;22.74,1.22,;21.41,1.99,;22.74,-.32,;24.08,-1.1,;25.41,-.32,;26.75,-1.09,;28.08,-.32,;26.75,-2.63,;25.41,-3.4,;25.41,-4.94,;26.75,-5.71,;28.09,-4.93,;28.08,-3.39,;29.41,-2.62,)| | ||
| Structure | 
| ||